NEW YORK SOCIETY FOR GASTROENTEROLOGY & ENDOSCOPY

#### 48th Annual NEW YORK COURSE December 12-13, 2024 • New York, NY



# Celiac Mimickers: A Sheep in Wolf's Clothing






Amy S. Oxentenko, MD FACP, FACG Professor of Medicine, Mayo Clinic College of Medicine & Science Vice Dean of Practice, Mayo Clinic Consultant, Division of Gastroenterology/Hepatology

Oxentenko.amy@mayo.edu



### DISCLOSURES

### None... other than I consume gluten!




New York Society for Gastroenterology and Endoscopy

# **Objectives**

Detail	Identify	Outline
Detail the entities that can mimic celiac disease either clinically or histologically	Identify the clinical and/or histologic differences to be able to distinguish between the differing disorders	Outline an approach to the patient with serologically- negative enteropathy

A8th Annual New York Course

# **Normal Small Bowel**




### Goblet cell

### Lymphocyte


### Small bowel mucosa

Enterocyte

# **Celiac Disease**




- Flattened villi (partial/total)
- Crypt hyperplasia



- Increased IELs
- Chronic inflammatory cell infiltrate in lamina propria


# Early Histologic Mimickers

IELs, no atrophy (Marsh 1 and 2)




### Intraepithelial Lymphocytes (IELs):What is "Abnormal"?

 $2005: \ge 25$  IELs/100 epithelial cells (prior 40)



#### Excluding known CD, only 6.8% dx with CD



Shmidt E, Smyrk TC, Boswell CL, Enders FT, Oxentenko AS, GIE 2014;80:105-11.


### **Histologic Findings are Not Specific to CD**

- IELS:\*
- NSAIDS
- H. pylori
- SIBO
- Gastroenteritis
- IBD




Kakar S. AJG 2003. Mahadeva S. J Clin Path 2002. Hammer STG 2010.Shmidt E. GIE 2014.Aziz I. APT 2010.

### **Proposed Algorithm**



# Late Histologic Mimickers


Villous atrophy, partial/total (Marsh 3+)





# **Autoimmune Enteropathy**





Patey-Mariuad DE, et al. Mod Pathol 2009;22:95-102. Akram S, et al. CGH 2007;5:1282-90.

# **Autoimmune Enteropathy**


- Increased recognition
  - Equal M:F
  - Age mean 44-55 years
  - Delay in dx median 1.5 years
- Refractory diarrhea and nutritional issues
- No response to diets



Anti-goblet cell antibodies are common and non-specific. 30-40% prevalence in population of healthy + disease.


> Akram S, et al. CGH 2007;5:1282-90. Sharma A, et al. CGH 2018;16:887-83.

# **Autoimmune Enteropathy vs Others**




#### <u>Autoimmune</u>

- No goblet cells; no Paneth cells
- Surface IELs less prominent
- Lymphoplasmacytic infiltrate



#### **Other Enteropathies**

- Goblet and Paneth cells present
- Surface IELs more prominent






# **Collagenous Sprue**


- Clinical/histologic features of CD
  - Diarrhea, malabsorption

- Thick type 1 collagen
  - >10-20 um (reports of 260 um!)
  - Normal collagen < 5 microns
  - Half of a lymphocyte



Gastroenterology 2016;150:S307-8; BMJ Open Gastroenterol 2016; JGH 2017;32:120-7.


### **15 Year History of Collagenous Sprue (CS)**



B Al-Bawardy, et al.Gastroenterology, 2016;150:S307-8.,

### **Management of Collagenous Sprue (CS)**

- Review medications
  - Stop offenders
- Initiate gluten-free diet
  - If HLA permissive
- Immunosuppression
  - Budesonide, prednisone, AZA, infliximab, others



**Review the meds!!!** Gastroenterology 2016;150:S307-8;

BMJ Open Gastroenterol 2016; JGH 2017;32:120-7.




### **ARB-Induced Enteropathy**

Systematic review: 82 case reports/series + 5 comparative studies

Patients (#)	248	
Type of ARB used	Olmesartan (223; 94%) Telmisartan (5; 2.0%) Irbesartan (4; 1.6%) Valsartan (3; 1.2%) Losartan (2; 0.8%) Eprosartan (1; 0.4%)	Other meds causing enteropathy: • Checkpoint inhibitors • Mycophenylate mofetil • Methotrexate
Age range(years)	45-89	
Range of time on drug	2 weeks – 13 years mean/n	nedian 3 years other studies)
HLA DQ2 or 8 positivity	71.4% (checked in 59% of patients)	
Negative celiac serology	98.8% (checked in 68% of patients)	
Failure of response to GFD	97.7%	
Complete symptom remission	97.4%	

Kamal A, et al. Gastroenterol Rep 2019;7:162-7. Gentile NM. Mayo Clin Proc 2013; Ziegler TR. Gastroenterology 2003.

### Drug-Induced Enteropathy Management



# U.S. Food and Drug Administration Search FDA < back to Drug Safety and Availability</td>

FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil

- Consider in the patient with:
  - Serologically-negative enteropathy
  - Collagenous deposition a clue
- Olmesartan started months to years earlier, leading to a delay in diagnosis
- Treatment:
  - Stop the medication if able
  - For immunosuppression, reduce dose if able



### **Combined Variable Immunodeficiency (CVID)**

Impaired B cell differentiation, abnormal Ig production

Any age (most 20-45 at dx), M:F equal


+/-Respiratory and GI infections; delayed dx

Other features: autoimmunity, liver, lymphoma

#### **CVID Criteria**:

- IgG 2 SD below normal AND
- One other low Ig level (IgA or IgM) AND
- Failure to mount vaccine reaction
- Absence of other immunodeficiency

### **Combined Variable Immunodeficiency (CVID)**





### Histologic clues:

- Reduced plasma cells
  - 30% w/normal #
- IELs, villous atrophy
- Apoptosis, neutrophils
- "Empty" lamina propria

\*Daniels, et al. Am J Surg Pathol 2007;31:1800-12.

People can have <u>CVID and celiac disease</u>! Hard to diagnosis – serologies negative!






#### **Cornerstone of CVID Management:**


Immune globulin replacement; Infection prevention




# **Tropical Sprue**




### **Tropical Sprue**





Don't forget <u>travel</u> <u>history</u> in the evaluation of serologicallynegative enteropathy!

### **Proposed Algorithm**



### **Take-Home Points**

All enteropathy is not celiac disease, even though it is most common Look for other clinical, laboratory or histologic clues in the case of a serologically-negative enteropathy, and include careful med review and travel history



### THANK YOU!!!

#### EMAIL: OXENTENKO.AMY@MAYO.EDU



